Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, efficacy, and tolerability of sodium zirconium cyclosilicate SZC in children under 18 years old with hyperkalaemia, a condition involving high potassium levels. This phase 3, open-label study involves about 140 participants across roughly 46 sites in Europe, North America, and other locations. It starts with two age cohorts 6 to under 12 years and 12 to under 18 years, with potential expansion to younger cohorts based on data review by an independent monitoring committee. Treatment includes three phases the Correction Phase CP, Maintenance Phase MP, and Long-Term Maintenance Phase LTMP. Participants in CP receive SZC orally three times daily for up to 3 days until potassium levels normalize, with doses adjusted by body weight equivalent to adult doses of 5 g, 10 g, or 15 g. Those achieving normal potassium enter the MP, receiving once-daily SZC for 28 days with dose adjustments to maintain levels. Participants may then continue into the LTMP, following a similar dose regimen with monthly visits. Throughout the study, participants undergo blood tests, ECG monitoring, urine analyses, and safety assessments to track potassium levels, aldosterone, electrolytes, and kidney function. Researchers measure effectiveness by the ability to achieve and maintain normal potassium levels and monitor safety and tolerability in all phases. The study duration is about 28 weeks, including treatment and a safety follow-up one week after the last dose.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of puxitatug samrotecan compared to a physicians choice of chemotherapy doxorubicin or paclitaxel in adults with advanced or metastatic endometrial cancer that has progressed after platinum-based chemotherapy and anti-PD-1anti-PD-L1 therapy. This Phase III, randomized, open-label study focuses on participants selected for B7-H4 expression and who have received no more than two prior treatments for advanced disease. Participants will be randomly assigned to receive either puxitatug samrotecan intravenously every three weeks or chemotherapy chosen by their physician. Chemotherapy options include doxorubicin given intravenously every three weeks or paclitaxel administered intravenously on days 1, 8, and 15 in a 28-day cycle. The study plans to enroll about 700 participants worldwide and compare how long participants live without cancer progression and overall survival between the two groups. During the study, participants will have regular assessments of their cancer status and quality of life. These will include imaging scans to measure tumor response and tracking of symptoms and side effects. Researchers will monitor progression-free survival, overall survival, response rates, duration of response, and time until further treatments are needed. The study will last approximately three years for outcome assessment, with safety and quality of life monitored throughout.